Bystander cell killing mediated by TMPK-F105Y/AZT therapy drives a significant tumor mass reduction in a prostate cancer xenograft model.

<p>(A) Magnitude of bystander cell killing was evaluated following the delivery of the TMPK-F105Y suicide gene by direct intratumoral injection of LV/TMPK into established tumors in NOD/SCID mice (n=6). Reduction in tumor mass was assessed at the end of 6-day AZT treatment regimen (at 50mg/kg/day) by extraction of tumors and measurement of wet tumor weight. Statistical significance is indicated by an asterisk (* p<0.05). (B) Weight of individual extracted tumors is shown for each animal in the AZT-treated and vehicle-untreated groups.